SC
PACB icon

SouthState Corp’s Pacific Biosciences PACB Stock Holding History

SouthState Corp’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-500
Closed -$620 – 1530
2025
Q2 		$620 Buy
+500
New +$577 ﹤0.01% 1382

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return

SouthState Corp's PACB Position: Q3 2025 in Review

SouthState Corp sold out of Pacific Biosciences (PACB) in Q3 2025, closing a stake of 500 shares — an estimated $620 sold.

SouthState Corp first reported a position in PACB in Q2 2025 and held it in 1 quarter. The position peaked at $620 in Q2 2025. 208 funds tracked by Wall St. Rank hold PACB as of Q3 2025.

  • SouthState Corp reported no remaining Pacific Biosciences position as of Q3 2025 after selling out during the quarter.
  • SouthState Corp sold 500 Pacific Biosciences shares in Q3 2025, an estimated $620.
  • SouthState Corp first reported a position in Pacific Biosciences in Q2 2025 and held it in 1 quarter.
  • SouthState Corp's Pacific Biosciences position peaked at $620 in Q2 2025.
  • 208 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2025.

Based on SouthState Corp's 13F filing for Q3 2025, filed 5 Nov 2025.